Related Experiment Videos
De novo CD5+ diffuse large B-cell lymphomas express VH genes with somatic mutation
1The Second Department of Internal Medicine, Mie University School of Medicine, Tsu, Japan.
Blood
|March 7, 1998
Summary
De novo CD5+ diffuse large B-cell lymphoma (DLBCL) cells originate from a distinct B-1 subset, differing from chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). This finding is based on extensive somatic mutations in Ig heavy chain variable region genes.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- CD5+ diffuse large B-cell lymphoma (DLBCL) is a distinct B-cell neoplasm.
- The cellular origin of de novo CD5+ DLBCL remains unclear.
- Distinguishing DLBCL from other CD5+ B-cell neoplasms like CLL and MCL is crucial.
Purpose of the Study:
- To elucidate the cellular origin of de novo CD5+ DLBCL.
- To compare the Ig heavy chain variable region (IgVH) gene sequences of de novo CD5+ DLBCL with those of CLL and MCL.
- To investigate the immunophenotypic and clinical characteristics of de novo CD5+ DLBCL.
Main Methods:
- Analysis of Ig heavy chain variable region (IgVH) gene nucleotide sequences.
- Comparison of somatic mutation patterns and germline homology.
- Immunophenotypic analysis (CD21, CD23 expression).
- Clinical data review (site involvement).
Main Results:
- De novo CD5+ DLBCL cases exhibited extensive somatic mutations in IgVH genes (86.9%-95.2% homology to germline).
- In contrast, CLL and MCL showed minimal somatic mutations (97.6%-100% homology to germline).
- Antigen selection patterns were observed in 2/4 DLBCL cases.
- CD5+ DLBCL frequently involved extranodal sites and lymph nodes, with low expression of CD21 and CD23.
Conclusions:
- De novo CD5+ DLBCL cells are derived from a B-1 cell subset.
- This B-1 subset is distinct from the origins of CLL and MCL.
- IgVH gene mutation analysis is a valuable tool for determining B-cell neoplasm origins.